定點醫療診斷檢査動向 是由出版商Trimark Publications在2011年11月所出版的。
這份英文市場調查報告書包含189 Pages 價格從美金3400起跳。
本報告書為定點照護檢驗（POC）市場的現狀與預測、成長率、主要產品與研究開發的最新情報、市場的機會與課題等、概述如下。
第1章 概要
第2章 定點照護檢驗診斷檢査概要
- 主要動向
- 現在的市場動向與促進因子
- POCT的有效性
- POCT的新成長分類
- 臨床設施之POCT的優點
- 價格、償還問題
- 顧客分類
- 全球定點照護檢驗市場
- 地區的分布
- 新興技術
- POCT的課題
- POCT的問題點
- POCT的場所
- 技術開發的里程碑
- 從實驗室到患者的分散化促進因子
- 償還擴充
- POCT的競爭環境
- POCT的將來
第3章 POCT與即時檢査市場：市場分析摘要：規模、背景、成長、佔有率、競爭企業
第4章 美國的定點照護檢驗市場
第5章 歐洲的定點照護檢驗市場
第6章 日本的定點照護檢驗市場
第7章 中國的定點照護檢驗市場
第8章 印度的定點照護檢驗市場
第9章 其他的諸國的定點照護檢驗市場
第10章 救命急救中的定點照護檢驗作用
- 定點照護檢驗的技術多樣性
- 廣泛的POCT檢驗
- 單一平台之臨床實驗課題
- 與臨床實驗平台的接續性
- POCT使用的臨床成果的改善
- 將來的發展
- 對應救命急救的定點照護檢驗
- 救命急救檢査的需求
- 主要設備
- 主要優點
- 標準化系統
- 定點照護檢驗對中央實驗室的檢査
- POCT的財政的優點
- 能正當轉為POCT嗎
- 全體的成本面上的優點
- 臨床醫療中確保更多時間
- 將來的政策
第11章 定點照護檢驗動向與預測
第12章 定點照護檢驗部門的商業動向
- 部門整合
- 收購・認證契約・夥伴關係
- 理想的收購簡介
- POCT之產品幅
- 從POCT事業撤退的企業
- 市場浸透度的上昇
- 歐洲的營業成本
- 歐洲的診斷檢査的發展因子
- 歐洲的償還
- 歐洲的成本抑制
- 帶來競爭優勢的重要因子
- POCT之營業戰略
第13章 生物科技業界動向
第14章 政府的法規
第15章 透過第3者的償還的限制阻礙了銷售量
- 影響POCT試藥以及裝置的販售的第3者償還
- 償還成本分類
- 定點照護檢驗產品線的償還圖式
第16章 商業障壁
- 顧客的集中
- 與其他公司的激烈競争
- 智慧財產權的保護
- 醫師的接受
- 現在的POCT市場成長水準無法保證將來的成長
- 技術平台之追加應用
- 成長管理
- 行銷基礎設施開發的難度
第17章 企業簡介
第18章 FDA現在免除掉的檢査
圖表
Abstract
Point of care testing enables rapid diagnostic tests to be performed while the
patient is at the point of care facility where results can be obtained
immediately, rather than waiting hours or even days for outside lab results to
arrive. Point of care testing covers: blood glucose testing, blood gas and
electrolytes analysis, rapid coagulation testing, rapid cardiac markers
diagnostics, drugs of abuse screening, urine strips testing, pregnancy
testing, fecal occult blood analysis, food pathogens screening, hemoglobin
diagnostics, infectious disease testing and cholesterol screening. The purpose
of this TriMark Publications report is to describe the sector trends within
the point of care testing (POCT) diagnostic market. It examines those
measurement devices and their reagents and supplies that are utilized in
hospitals, clinics, commercial laboratories and research institutions to
detect cells and proteins for the purpose of diagnosis and monitoring of
disease. This study includes all of the generally-accepted clinical analytical
activities that are currently in use today. Additionally, an analysis of
business and technology trends and developing areas of point of care and HPV
testing is provided, along with a review of the market for point of care
testing equipment and supplies in the clinical and research market segments,
using screening reagents and instruments for analysis of individual components
in blood, serum or plasma. This report defines U.S. and global market dollar
sales volume and analyzes factors that influence the size and growth of market
segments.
METHODOLOGY
The author of this report holds a Ph.D. in biochemistry from the University of
Minnesota and has had post-doctoral experience at the University of
Connecticut School of Medicine. He has taught at Quinnipiac University and the
Tufts School of Medicine, and has been a senior scientist at Pfizer
Pharmaceutical Laboratories in drug development. He also has many decades of
experience in science writing and as a medical industry analyst. He has over
30 years of experience in laboratory testing and instrument and reagent
development technology as a licensed clinical laboratory director, as well as
extensive experience in senior level management positions in biotech and
medical service companies. The editor of this report is a Ph.D. in
biochemistry from the University of Liverpool with many decades of experience
in science writing and as a medical industry analyst.
Company-specific information is obtained mainly from industry trade
publications, academic journals, news and research articles, press releases
and corporate websites, as well as annual reports for publicly-held firms.
Additional sources of information include non-governmental organizations
(NGOs) such as the World Health Organization (WHO) and governmental entities
such as the U.S. Department of Health and Human Services (HHS), the National
Institutes of Health (NIH), the Food and Drug Administration (FDA) and the
Centers for Disease Control and Prevention (CDC). Where possible and
practicable, the most recent data available have been used.
Some of the statistical information was taken from Biotechnology Associates'
databases and from TriMark's private data stores. The information in this
study was obtained from sources that we believe to be reliable, but we do not
guarantee the accuracy, adequacy or completeness of any information or
omission or for the results obtained by the use of such information. Key
information from the business literature was used as a basis to conduct
dialogue with and obtain expert opinion from market professionals regarding
commercial potential and market sizes. Senior managers from major company
players were interviewed for part of the information in this report.
Table of Contents
1. Overview
- 1.1. Statement of Report
- 1.2. Scope of This Report
- 1.3. Objectives
- 1.4. Methodology
- 1.5. Executive Summary
2. Overview of Point of Care Diagnostic Testing
- 2.1. Key Issues in the Point of Care Diagnostic Testing Sector
- 2.1.1. Current Market Trends and Drivers
- 2.1.2. Effectiveness of POCT
- 2.1.3. New Growth Areas for POCT
- 2.1.4. Advantages of POCT in a Clinical Setting
- 2.1.5. Pricing and Reimbursement Issues
- 2.1.6. Key Customer Segments
- 2.2. Global Point of Care Marketplace
- 2.3. Shifts from Central Lab Testing to POCT
- 2.4. Geographical Distribution
- 2.5. Emerging New Technologies
- 2.6. Challenges of POCT
- 2.7. Key Issues for POCT
- 2.7.1. Locations of POCT
- 2.7.2. Milestones in Technology Development
- 2.7.3. Drive for Decentralization from Lab to Patient
- 2.7.4. Expanded Reimbursement
- 2.7.5. Competitive Landscape for POCT
- 2.8. The Future of POCT
3. POC and Rapid Testing Market: Summary of Market Analysis: Size, Background, Growth, Share and Competitors
4. U.S. POCT Market
5. European POCT Market
6. Japanese POCT Market Sector Trends
7. Chinese POCT Market Sector Trends
8. Indian POCT Market Sector Trends
9. The Rest of the World (ROW) POCT Market
10. The Role of POCT in Critical Care
- 10.1. Technological Diversity in POCT
- 10.1.1. The Wide Range of Point of Care Assays
- 10.1.2. Challenge of Testing on a Single Platform
- 10.1.3. Connectivity with Testing Platforms
- 10.1.4. Improvement in Clinical Outcomes with Use of POCT
- 10.1.5. Future Developments
- 10.2. Point of Care Addresses Critical Requirements
- 10.2.1. Needs in Critical Care Testing
- 10.2.2. Point of Care Instrument Key Elements
- 10.2.3. Key Advancements--Menu, Quality Assurance (QA), Connectivity,
Internet Access
- 10.2.4. Standardized System for All Testing Locations
- 10.3. POCT versus Central Laboratory Testing
- 10.3.1. The Financial Advantages of POCT
- 10.3.2. Is the Shift Towards Point of Care Justified?
- 10.3.3. Overall Cost Benefit
- 10.3.4. More Available Time for Clinical Practitioners
- 10.3.5. Future Policies
11. POCT Sector Trends and Market Predictions
12. Business Trends in the Point of Care Sector
- 12.1. Sector Consolidation
- 12.2. Acquisition, License Agreements, Internal Development and
Partnerships
- 12.3. The Ideal Acquisition Profile
- 12.3.1. Markets of Interest for Acquisition of POCT
- 12.3.2. Key M&A Steps
- 12.4. Product Breadth in POCT
- 12.5. Companies Exiting From POCT
- 12.6. Increased Market Penetration
- 12.7. Costs of Doing Business in Europe
- 12.8. Drivers of European Diagnostics Testing
- 12.9. European Reimbursement Practices
- 12.10. Cost Containment in Europe
- 12.11. Significant Factors that Provide Competitive Advantage
- 12.12. Sales and Marketing Strategies for POCT
- 12.12.1. North American Market
- 12.12.2. International Markets
- 12.12.2.1. Europe
- 12.12.2.2. Central and South America
- 12.12.2.3. Asia-Pacific
13. Biotechnology Industry Trends
- 13.1. Pharmaceutical Industry Trends
14. Government Regulation
- 14.1. Government Regulation
- 14.1.1. U.S. Regulation
- 14.1.1.1. Importing Medical Devices into the U.S.
- 14.1.1.2. Exporting Medical Devices from the U.S.
- 14.1.2. E.U. Regulations
- 14.1.3. Japanese Regulations
- 14.1.4. Korean Regulations
- 14.2. Post Filing Regulations for Point of Care Devices
- 14.3. Exporting Unapproved POCTs
- 14.4. Analyte Specific Reagents (Home Brew Tests)
- 14.5. Medical Device Registration
- 14.6. Product Labeling
- 14.7. Punitive FDA Actions
- 14.8. Clinical Laboratory Improvement Act of 1988 and State Laboratory Laws
- 14.9. Impact of Regulations on the Industry
- 14.10. Minimizing Regulatory Barriers
- 14.11. Waived Testing
15. Limited Reimbursements by Third-Party Payers Obstruct Sales
- 15.1. Third-Party Reimbursement Impact on POCT Reagents and Devices Sales
- 15.2. Reimbursement Codes Classification
- 15.3. Point of Care Product Line Reimbursement Picture
16. Barriers to Business
- 16.1. Concentration of Customers
- 16.2. Intense Competition from Other Companies
- 16.3. Protection of Intellectual Property Rights
- 16.4. Physician Acceptance
- 16.5. Current Levels of Market Growth for POCT Procedures May Not be
Indicative of Future Growth
- 16.6. Additional Applications of Technology Platform
- 16.7. Management of Growth
- 16.8. Difficulty of Establishing a Marketing Infrastructure
17. Company Profiles
- 17.1. Abaxis, Inc.
- 17.2. Abbott Diagnostics
- 17.3. Accumetrics, Inc.
- 17.4. Accurex Biomedical Pvt. Ltd.
- 17.5. AgaMatrix
- 17.6. Akers Bioscience, Inc. (ABI)
- 17.7. Alfa Scientific Design, Inc.
- 17.8. Alere Health, LLC
- 17.9. Ambri Ltd.
- 17.10. American Bio Medica Corporation
- 17.11. Ani Biotech
- 17.12. Apogent Technologies
- 17.13. Ark Therapeutics
- 17.14. ARKRAY, Inc.
- 17.15. Atlas Genetics
- 17.16. Atonomics A/S
- 17.17. Avox Systems
- 17.18. Axis-Shield
- 17.19. Bayer Corp.
- 17.20. Beacon Diagnostics, Inc.
- 17.21. Beckman Coulter
- 17.22. Binax Corporation
- 17.23. Biomerica, Inc.
- 17.24. bioMerieux
- 17.25. BioScan Screening Systems, Inc.
- 17.26. Biosite Diagnostics
- 17.27. British Biocell Holdings
- 17.28. Caliper Life Sciences
- 17.29. Calypte Biomedical Corporation
- 17.30. Chembio Diagnostics, Inc.
- 17.31. Cholestech
- 17.32. CompuCyte Corporation
- 17.33. Cozart Bioscience
- 17.34. Cygnus Therapeutic Systems
- 17.35. Cytogen Corporation
- 17.36. Dade Behring
- 17.37. Daiichi Sankyo Group
- 17.38. Denka Seiken Co., Ltd.
- 17.39. Diagnostic Chemicals Ltd.
- 17.40. EY Laboratories, Inc.
- 17.41. Enterix, Inc.
- 17.42. Focus Diagnostic, Inc.
- 17.43. GDS Technology
- 17.44. GenBio
- 17.45. Genzyme Diagnostics
- 17.46. Grant Life Sciences, Inc.
- 17.47. Gryphus Diagnostics, LLC
- 17.48. Guided Therapeutics, Inc.
- 17.49. Harring Group Ltd. (HGR)
- 17.50. Helena Laboratories
- 17.51. Hema Diagnostic Systems, LLC
- 17.52. HemoCue, Inc.
- 17.53. Home Access Health Corp.
- 17.54. i-STAT Corporation
- 17.55. ImmunoScience, Inc.
- 17.56. Instrumentation Laboratory
- 17.57. International Medical Innovations
- 17.58. Johnson & Johnson
- 17.59. LifeAssays AB
- 17.60. MediSense
- 17.61. Medisys
- 17.62. Medix Biochemica
- 17.63. MedMira Laboratories
- 17.64. Medtronic
- 17.65. A Menarini Diagnostics
- 17.66. Meretek Diagnostics Group
- 17.67. Meridian Bioscience
- 17.68. MiniMed
- 17.69. Mitsubishi Chemical USA, Inc.
- 17.70. Mitsubishi Kagaku Iatron
- 17.71. Nanogen (ELITech Group)
- 17.72. New Horizons Diagnostics
- 17.73. Nova Biomedical
- 17.74. OraSure Technologies, Inc.
- 17.75. Orgenics
- 17.76. Orion Diagnostica
- 17.77. PanBio Ltd.
- 17.78. Phamatech, Inc.
- 17.79. PharmaNetics, Inc.
- 17.80. Polymedco, Inc.
- 17.81. Polymer Technology Systems, Inc.
- 17.82. Princeton BioMeditech Corporation
- 17.83. Quest Diagnostics, Inc.
- 17.84. Quidel Corporation
- 17.85. Radiometer
- 17.86. Response Biomedical Corp.
- 17.87. Roche Diagnostics
- 17.88. Savyon Diagnostics
- 17.89. Selfcare, Inc.
- 17.90. Shionogi & Co., Ltd.
- 17.91. Siemens Corporation
- 17.92. Guided Therapeutics (SpectRx, Inc.)
- 17.93. Spectral Diagnostics
- 17.94. StatSure Diagnostic Systems, Inc.
- 17.95. Strategic Diagnostics
- 17.96. Trinity Biotech, Plc
- 17.97. Vasamed, Inc.
18. FDA Currently Waived Tests
INDEX OF FIGURES
- Figure 14.1: Conformity Assessment Route, Annexes and Quality System
Standards by IVD Device Category
INDEX OF TABLES
- Table 2.1: POCT Frequency in Hospitals
- Table 2.2: Worldwide Distribution of IVD Testing, 2010
- Table 2.3: Top Thirteen Country IVD Testing Markets, 2010
- Table 2.4: Common Genotype Techniques
- Table 2.5: Competitive Landscape for Point of Care Diagnostic Testing
- Table 3.1: Total Global POCT Market, 2007-2017
- Table 3.2: Global Revenue Forecasts for POC Blood Glucose Monitoring
Systems, 2007-2017
- Table 3.3: Global Revenue Forecasts for POC Blood Gas and Electrolyte
Analyzers, 2007-2017
- Table 3.4: Global Revenue Forecasts for POC Rapid Coagulation Analyzer
Systems, 2007-2017
- Table 3.5: Global Revenue Forecasts for POC Cardiac Marker Devices,
2007-2017
- Table 3.6: Global Revenue Forecasts for POC Substance/Drug Abuse Testing
Device Market, 2007-2017
- Table 3.7: Global Revenue Forecasts for POC Infectious Disease Testing
Devices Market, 2007-2017
- Table 3.8: Global Revenue Forecasts for POC Urine Strip Testing Products
Market, 2007-2017
- Table 3.9: Global Revenue Forecasts for POC Pregnancy Testing Devices
Market, 2007-2017
- Table 3.10: Global Revenue Forecasts for POC Fecal Occult Testing Devices
Market, 2007-2017
- Table 3.11: Global Revenue Forecasts for POC Cholesterol Testing Products
Market, 2007-2017
- Table 3.12: Global Market Share Analysis, 2010
- Table 4.1: Total U.S. POCT Market for Blood Glucose Monitoring Systems,
2007-2017
- Table 4.2: U.S Revenue Forecasts for POC Blood Glucose Monitoring Systems,
2007-2017
- Table 4.3: U.S Revenue Forecasts for POC Blood Gas and Electrolyte
Analyzers, 2007-2017
- Table 4.4: U.S. Revenue Forecasts for POC Rapid Coagulation Analyzer
Systems, 2007-2017
- Table 4.5: U.S. Revenue Forecasts for POC Cardiac Marker Devices, 2007-2017
- Table 4.6: U.S. Revenue Forecasts for POC Substance/Drug Abuse Testing
Device Market, 2007-2017
- Table 4.7: U.S. Revenue Forecasts for POC Infectious Disease Testing
Devices Market, 2007-2017
- Table 4.8: U.S. Revenue Forecasts for POC Urine Strip Testing Products
Market, 2007-2017
- Table 4.9: U.S. Revenue Forecasts for POC Pregnancy Testing Devices
Market, 2007-2017
- Table 4.10: U.S. Revenue Forecasts for POC Fecal Occult Testing Devices
Market, 2007-2017
- Table 4.11: U.S. Revenue Forecasts for POC Cholesterol Testing Products
Market, 2007-2017
- Table 4.12: U.S. Market Share Analysis, 2010
- Table 5.1: Models of Public-Private Partnership in Hospital Provision
- Table 5.2: European Revenue Forecasts for POCT Market, 2007-2017
- Table 5.3: European Revenue Forecasts for POC Blood Glucose Monitoring
Systems, 2007-2017
- Table 5.4: European Revenue Forecasts for POC Blood Gas and Electrolyte
Analyzers, 2007-2017
- Table 5.5: European Revenue Forecasts for POC Rapid Coagulation Analyzer
Systems, 2007-2017
- Table 5.6: European Revenue Forecasts for POC Cardiac Marker Devices,
2007-2017
- Table 5.7: European Revenue Forecasts for POC Substance/Drug Abuse Testing
Device Market, 2007-2017
- Table 5.8: European Revenue Forecasts for POC Infectious Disease Testing
Devices Market, 2007-2017
- Table 5.9: European Revenue Forecasts for POC Urine Strip Testing Products
Market, 2007-2017
- Table 5.10: European Revenue Forecasts for POC Pregnancy Testing Devices
Market, 2007-2017
- Table 5.11: European Revenue Forecasts for POC Fecal Occult Testing
Devices Market, 2007-2017
- Table 5.12: European Revenue Forecasts for POC Cholesterol Testing
Products Market, 2007-2017
- Table 5.13: European Market Share Analysis, 2010
- Table 6.1: Total Japanese POCT Market, 2007-2017
- Table 6.2: Japanese Revenue Forecasts for POC Blood Glucose Monitoring
Systems, 2007-2017
- Table 6.3: Japanese Revenue Forecasts for POC Blood Gas and Electrolytes
Systems Analysis, 2007-2017
- Table 6.4: Japanese Revenue Forecasts for POC Rapid Coagulation Analyzer
Systems, 2007-2017
- Table 6.5: Japanese Revenue Forecasts for POC Cardiac Marker Devices,
2007-2017
- Table 6.6: Japanese Revenue Forecasts for POC Substance/Drug Abuse Testing
Device Market, 2007-2017
- Table 6.7: Japanese Revenue Forecasts for POC Infectious Disease Testing
Devices Market, 2007-2017
- Table 6.8: Japanese Revenue Forecasts for POC Urine Strip Testing Products
Market, 2007-2017
- Table 6.9: Japanese Revenue Forecasts for POC Pregnancy Testing Devices
Market, 2007-2017
- Table 6.10: Japanese Revenue Forecasts for POC Fecal Occult Testing
Devices Market, 2007-2017
- Table 6.11: Japanese Revenue Forecasts for POC Cholesterol Testing
Products Market, 2007-2017
- Table 6.12: Japanese Market Share Analysis, 2010
- Table 9.1: ROW Revenue Forecasts for POC Market, 2007-2017
- Table 9.2: ROW Revenue Forecasts for POC Blood Glucose Monitoring Systems,
2007-2017
- Table 9.3: ROW Revenue Forecasts for POC Blood Gas and Electrolytes
Systems Analysis, 2007-2017
- Table 9.4: ROW Revenue Forecasts for POC Rapid Coagulation Analyzer
Systems, 2007-2017
- Table 9.5: ROW Revenue Forecasts for POC Cardiac Marker Devices Market,
2007-2017
- Table 9.6: ROW Revenue Forecasts for POC Substance/Drug Abuse Testing
Devices Market, 2007-2017
- Table 9.7: ROW Revenue Forecasts for POC Infectious Disease Testing
Devices Market, 2007-2017
- Table 9.8: ROW Revenue Forecasts for POC Urine Strip Testing Products
Market, 2007-2017
- Table 9.9: ROW Revenue Forecasts for POC Pregnancy Testing Devices Market,
2007-2017
- Table 9.10: ROW Revenue Forecasts for POC Fecal Occult Testing Devices
Market, 2007-2017
- Table 9.11: ROW Revenue Forecasts for POC Cholesterol Testing Products
Market, 2007-2017
- Table 9.12: ROW Market Share Analysis, 2010
- Table 10.1: Customized Reports Must Support CAP and JCAHO Requirements
- Table 17.1: Abaxis, Inc. Financial Figures--Net Sales by Business Sector,
2008-2010
- Table 17.2: Abaxis, Inc. Financial Figures--Net Sales by Geographic
Region, 2008-2010
- Table 17.3: Abbott Laboratories Financial Figures--Net Sales by Business
Sector, 2008-2010
- Table 17.4: Abbott Laboratories Financial Figures--Net Sales by Geographic
Region, 2008-2010
- Table 17.5: Bayer AG Financial Figures--Net Sales by Business Sector,
2008-2010
- Table 17.6: Bayer AG Financial Figures--Net Sales by Geographic Region,
2008-2010
- Table 17.7: Johnson & Johnson Financial Figures--Net Sales by Major
Medical and Diagnostics Businesses, 2008-2010
- Table 17.8: Medtronic Financial Figures--Net Sales by Segment, 2008-2010
- Table 17.9: Quidel Product Sales Distribution and Sales, 2009 and 2010
- Table 17.10: Danaher Corporation Financial Figures--Net Sales by Business
Sector, 2008-2010
- Table 17.11: Danaher Corporation Financial Figures--Net Sales by
Geographic Region, 2008-2010
- Table 17.12: Roche Group Financial Figures--Net Sales by Business Sector,
2008-2010
- Table 17.13: Roche Group Financial Figures--Net Sales by Geographic
Region, 2009 and 2010
- Table 17.14: Roche Group Financial Figures--Net Sales by Sub-Division,
2008-2010
- Table 2.1: POCT Frequency in Hospitals
- Table 2.2: Worldwide Distribution of IVD Testing in 2008
- Table 2.3: Top Twelve Country IVD Testing Markets, 2007
- Table 2.4: Competitive Landscape for Point of Care Diagnostic Testing
- Table 3.1: Actual Reported Number of ER Visits in U.S. Hospitals, 1997-2008
- Table 3.2: Number of POCTs in U.S., 2004-2012
- Table 3.3: Overall In Vitro Diagnostic Testing Market Worldwide, 2007
- Table 3.4: Largest Diagnostic Companies Worldwide, 2007
- Table 3.5: Global Point of Care Revenues, 2005-2012
- Table 3.6: Worldwide Distribution of POCT, 2008
- Table 3.7: Professional Glucose Testing Market for POCT Worldwide,
2001-2012
- Table 3.8: U.S. POCT Market, 2000-2012
- Table 3.9: U.S. Clinical Laboratory Diagnostic Test Market Segments by
Location of Analysis, 2008
- Table 3.10: U.S. POCT by Performance Location, 2008
- Table 3.11: U.S. Clinical Diagnostic POCT and Rapid Test Market Segments,
2007
- Table 3.12: U.S. POCT Glucose Testing Market, 2003-2012
- Table 3.13: U.S. POCT Blood Gas and Electrolytes Market Size, 2003-2012
- Table 3.14: U.S. POCT Coagulation Market Size, 2003-2012
- Table 3.15: U.S. POCT Cardiac Markers Market Size, 2003-2012
- Table 3.16: U.S. POCT Dedicated Primary Care Markers Market Size, 2003-2012
- Table 3.17: U.S. POCT Urinalysis Market Size, 2003-2012
- Table 3.18: Manufacturer Market Share U.S. POCT Market, 2008
- Table 3.19: Manufacturer Market Share U.S. POCT Market Glucose Testing,
2008
- Table 3.20: Manufacturer Market Share U.S. POCT Blood Gas and Electrolytes
Market, 2008
- Table 3.21: Manufacturer Market Share U.S. POCT Coagulation Market, 2008
- Table 3.22: Manufacturer Market Share U.S. POCT Cardiac Marker Market, 2008
- Table 3.23: Regional Comparison of Healthcare Spending for IVD for Eastern
Europe
- Table 3.24: European POCT Market, 2005-2012
- Table 3.25: European POCT Diagnostics Market, 2007
- Table 3.26: Top Twelve Country IVD and POC Testing Markets, 2007
- Table 3.27: Japan POCT Market, 2005-2012
- Table 4.1: Customized Reports Must Support CAP and JCAHO Requirements
- Table 12.1: Products Marketed by Abbott in the Diagnostic Market
- Table 12.2: Quidel Product Sales Distribution and Sales, 2006-2008
- Table 12.3: Key Products
|
